Android app on Google Play

Jefferies Maintains a 'Buy' on Amarin (AMRN); Concern Over NCE Delay And Meta-analysis Presents A Buying Opportunity

September 12, 2012 7:08 AM EDT Send to a Friend
Get Alerts AMRN Hot Sheet
Price: $1.93 --0%

Rating Summary:
    4 Buy, 14 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade AMRN Now!
Join SI Premium – FREE
Jefferies maintains a 'Buy' on Amarin Corporation (NASDAQ: AMRN) price target of $28.00.

Analyst, Thomas Wei, said, "We believe investor speculation over further delays in Vascepa’s New Chemical Entity (NCE) decision, plus a minor concern for a new meta-analysis, has contributed to stock weakness. We believe the stock reaction creates an attractive entry point, as we do not believe NCE status is essential for a pharma deal given the patent prospects or that the analysis of 1-2 gram Lovaza studies predicts the outcome of Vascepa’s REDUCE-IT trial."

For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.

Shares of Amarin Corporation closed at $13.56 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment